Advertisement
Chronic dosing of apricot kernel extract can result in hypoxia and cyanide toxicity

Chronic Dosing of Apricot Kernel Extract May Lead to Hypoxia

0
Self-prescription of kernel extract reported for five years; cyanide toxicity confirmed in blood analysis
The top 10 percent of privately insured U.S. adults without cancer using opioids account for most opioid use

Most Opioid Use Concentrated in Top 10 Percent of Users

0
Top 10 percent of users accounted for 76 percent of the total annual morphine equivalents
Recommendations for the management and pharmacologic treatment of patients with diabetes have been updated; the new clinical guidelines were published online Sept. 12 in the Annals of Internal Medicine.

2017 Standards of Medical Care in Diabetes Released

0
Recommendations for T1D focus on monitoring, pharmacologic approaches to glycemic management
A specific subset of tissue factor-expressing monocytes persist after virological suppression and trigger the coagulation cascade by activating factor X in HIV

In HIV, Tissue Factor-Expressing Monocytes Trigger Coagulation

0
The anticoagulant Ixolaris blocked functional activity of tissue factor in vitro and in vivo
Women on antiepileptic drugs during pregnancy for epilepsy or other indications are at increased risk of giving birth to premature and small-for-gestational-age infants

Risk of Prematurity, SGA Up for Women on Antiepileptic Drugs

0
Increased risk for women on AEDs for epilepsy or other indications; risk varies with drug used
Neurological complications associated with anti-programmed death 1 antibody treatment have a diverse phenotype

Diverse Neurological Effects Linked to Anti-PD-1 Therapy

0
Complications seen after median of 5.5 cycles of anti-PD-1-inhibitors; include myopathy, neuropathies
A 10-mL 1 percent lidocaine paracervical nerve block reduces pain during intrauterine device insertion

Lidocaine Nerve Block Reduces Pain During IUD Insertion

0
Pain score lower among patients who receive lidocaine than those who receive placebo
For patients with locally advanced

Longer Progression-Free Survival for Durvalumab in NSCLC

0
Longer median progression-free survival from randomization, higher response rate with durvalumab
The median cost of cancer drug development is $648.0 million

Median Cost of Cancer Drug Development $648.0 Million

0
Total revenue from sales of 10 drugs was $67.0 billion, with total R&D spending of $7.2 billion
Romosozumab treatment followed by alendronate is linked to reduced risk of fractures versus alendronate alone for postmenopausal women with osteoporosis

ASBMR: Romosozumab Reduces Fracture Rate in Osteoporosis

0
Reduced risk of new vertebral fractures, nonvertebral fractures for romosozumab and alendronate